Yttrium-90 Microsphere Therapy Planning and Dose Calculations

S. Cheenu Kappadath, PhD, DABR, DABSNM

Department of Imaging Physics
The University of Texas MD Anderson Cancer Center
Houston, Texas, USA

THE UNIVERSITY OF TEXAS
MD Anderson Cancer Center
Making Cancer History®

Educational Objectives

- To understand the imaging sequence for Yttrium-90 microsphere therapy
- To understand calculation of lung shunt fraction and estimation of absorbed dose for lung and liver
- To become familiar with radiation safety and regulations surrounding Yttrium-90 microsphere therapy

Outline

- Overview of ^{90}Y-microsphere therapy
- Patient imaging prior to ^{90}Y-microsphere therapy
- Lung shunt fraction and lung dose calculations
- ^{90}Y-microsphere therapy dose calculations
- Patient imaging post ^{90}Y-microsphere therapy
- Three-compartment partition model
- Measurement of ^{90}Y activity and admin. activity
- Radiation Safety
- Challenges and Summary

^{90}Y-microsphere Therapy

- Trans-arterial delivery of radioactive ^{90}Y-labeled microspheres via a catheter directly at disease sites (targeted infusion)
- Microspheres (20-30 µm) trapped in tumor capillary vessels due to their embolic size and targeted delivery



© TheraSphere

© SIRTEX





- β emissions from trapped ^{90}Y-microspheres are capable of delivering lethal radiation doses to (proximal) neoplastic tissue while sparing (more distal) surrounding normal tissue

^{90}Y-microsphere Therapy

- ^{90}Y-microsphere therapy usually target the liver
- ^{90}Y-microsphere therapy takes advantage of the unique circulatory system in the liver
  - Portal vein (normal liver) & hepatic artery (tumor)
- Liver directed XRT are limited in scope
  - Radiation tolerance of normal hepatocytes < neoplastic tissue
  - Max. tolerated doses 30–40 Gy (Emami et al, IJROBP 21, 1991; McGinn et al, J Clin Onc 16, 1998)
- With ^{90}Y-microspheres, total liver radiation doses up to 80 Gy were well tolerated with no hepatic radiation damage (Gray et al, Annals Oncology 12, 2001; Burton et al, Radiology 175, 1990)
- ^{90}Y-microsphere therapy is approved by the FDA for the treatment of unresectable HCC and metastatic colorectal cancer

Properties of Yttrium-90

- Decay: Y-90 (β^-, 64.1 hr) Zr-90; a pure β^- emitter
  - Y-90 also emits β^+ at low yields (~32 ppm) via internal pair-production
- β energy: 0.937 MeV (mean) and 2.28 MeV (max)
- Tissue penetration depth: 2.5 mm (mean) and 11 mm (max)
- ^{90}Y deposits >90% of its energy in the first 5 mm of tissue
- ^{90}Y deposits >90% of its energy in the first 11 days
- Permanently implanted ^{90}Y can deliver radiation absorbed doses of ~50 Gy for 1 GBq of activity per kilogram of tissue

(Berger, JNM 12, 1971)





(Sarfaraz et al., Med Phys 31, 2004)

Commercial ^{90}Y-microsphere Products

SIR-Spheres®

- Sirtex Medical, Sydney, Australia
- Insoluble, biocompatible resin matrix
- 30–35 µm glass spheres
- 3 GBq (81 mCi) activity = 30–60 x 10^6 spheres
- Maximum activity available: 3 GBq (81 mCi)
- Indicated for the treatment of unresectable metastatic liver tumors from primary colorectal cancer with adjuvant chemotherapy (FUDR)

TheraSphere®

- MDS Nordion, Ottawa, Canada
- Insoluble, biocompatible glass matrix
- 20–30 µm glass spheres
- 3 GBq (81 mCi) activity = ~1.2 x 10^6 spheres
- Maximum activity available: 20 GBq (540 mCi)
- Indicated for radiation treatment or as a neoadjuvant for surgery or transplantation in patients with unresectable HCC

Liver is common site of metastases from a variety of neoplasms
→ Clinical trials on management of metastatic liver disease

Patient Imaging Prior to ^{90}Y Therapy

- CT or MRI – Estimate target tumor mass
- IR – Se… ure
  - Int. … graphy suite
- NM – 9…
  - MAA…
  - Asse… tumors


(Hall et al., J Int Onc 2, 2009)

Lung Dose Consideration

- Prevention of radiation pneumonitis
  - Arterio-venous shunting in neoplastic vasculature
  - Tc-99m MAA scans used to assess lung shunt fraction and lung dose
  - Exclude patients with lung shunting that could result in lung radiation dose >25-30 Gy per treatment or >50 Gy cumulative

(Ho et al, EJNM 24, 1997)

SIR-Spheres	
Lung Shunting	Reduction Factor
<10 %	No Reduction
10 % - 15 %	20 % reduction
15 % - 20 %	40 % reduction
> 20 %	No Treatment
Lung dose per treatment < 25 Gy	

TheraSphere	
Lung Dose Limit	Gy
Per Treatment	30
Cumulative	50

Lung Shunt (LS) Fraction

- 2-4 mCi of ^{99m}Tc-MAA delivered trans-arterially in IR suite
- Planar scintigraphy of Thorax and Abdomen (AP and PA)
- Calculate Lung Shunt (LS) using the following formula

$$\text{Lung Shunt}(\%) = \frac{\text{Lung Counts}}{\text{Lung Counts} + \text{Liver Counts}} \times 100$$

$$\text{GM counts} = \sqrt{ANTcounts \times POSTcounts}$$

- SIR-Spheres: geometric-mean images
- TheraSphere: not specified



Example Lung Shunt Calculation

LS (%) = Lung GM-counts / (Lung GM-counts + Liver GM-counts) x 100
= 77278 / (77278 + 973962) x 100 = 7.35%

- SIR-Spheres:
  LS < 10% (no modification)
  → 81 mCi ^{90}Y activity limit
- TheraSphere:
  30 Gy lung dose limit
  → 222 mCi ^{90}Y activity limit

	Left	Right
Lung ANT	38787	44174
Lung POST	34282	37703
Liver ANT	1641103	
Liver POST	578027	
	GM Lung Total	77278
	GM Liver Total	973962
	% Lung Shunt	**7.35%**

^{90}Y-Therapy Planning: SIR-Spheres

- SIR-Spheres therapy doses are based on activity (not target radiation dose) – maximum activity of 81 mCi
- Empirical dosimetry models
  - Basic: Activity based on maximum activity & tumor fraction
  - BSA: Activity based on BSA & tumor involvement in liver
  - Lung Shunt modification: No treatment for LS > 20%
- Average liver dose < 80 Gy and lung dose < 25 Gy

Tumor Fraction Modification	
Tumor fraction in liver	Recommended ^{90}Y-activity
> 50 %	3.0 GBq (81 mCi)
25 - 50 %	2.5 GBq (67.5 mCi)
< 25 %	2.0 GBq (54 mCi)

Lung-Shunt Fraction Modification	
Lung Shunting	Reduction Factor
<10 %	No Reduction
10 % - 15 %	20 % reduction
15 % - 20 %	40 % reduction
> 20 %	No Treatment
Lung dose per treatment < 25 Gy	

^{90}Y-Therapy Planning: TheraSphere

- TheraSphere therapy doses are based on desired radiation dose to target mass; typically 120 to 150 Gy

$$\text{Activity Required [GBq]} = \frac{\text{Desired Dose [Gy] x Target Mass [kg]}}{\text{50 [Gy-kg/GBq]}}$$

- Target mass = whole liver or liver lobe or liver segment
  - Patient-specific vasculature and catheter approach (common or left or right hepatic artery) to target mass defines target mass
- Therapy must maintain lung dose lower than 30 Gy
  - Maximum activity depends on the Lung Shunt fraction

Radiation Absorbed Dose

- $Dose_{tissue}$ [Gy] = A_{tissue} [GBq] x 49.7 [Gy-kg/GBq] / M_{tissue} [kg]
  - Self dose from β emission: >90% energy deposit in <5mm
  - 49.7 [Gy-kg/GBq] = equilibrium accumulated dose constant
  - Bremsstrahlung dose << β dose

(Berger, JNM 12, 1971; Stabin et al, JNM 35, 1994; Gulec et al, JNM 47, 2006)

Liver Dose [Gy] [illegible] GBq] / M_{liver} [kg]

Lung Dose [Gy] [illegible] / M_{lung} [kg]



- Error in liver mass propagates into liver dose calculation
- Model estimates average dose to target volume assuming uniform microsphere uptake within volume

Dose Calculations: TheraSphere

Max Activity [mCi] = 30 [Gy] x M_{lung} [kg] / (LS x 0.037 [GBq/mCi] x 49.7 [Gy-kg/GBq])

Activity [mCi] = D_{liver} [Gy] x M_{liver} [kg] / ((1-LS) x 0.037 [GBq/mCi] x 49.7 [Gy-kg/GBq])

- Lung Shunt = 0.0735
- Maximum Activity = 222 mCi, for lung dose = 30 Gy
- Liver dose [Gy] = 378 [Gy-kg] / M_{liver} [kg]
  = 198 Gy for M_{liver} = 1.91 kg (MIRD Std. Man)
  = 154 Gy for M_{liver} = 2.46 kg (Weight-based)
  = 137 Gy for M_{liver} = 2.76 kg (CT-based)

- Target liver dose = 120 Gy
  → 134.6 mCi of ^{90}Y → Lung dose delivered = 18.2 Gy

Dose Calculations: SIR-Spheres

M, 53 kg, 174.5 cm → BSA = 1.60 m²		
Tumor involvement (TI)	45%	Dose modification YES
Lung Shunt (LS)	7.35%	Dose modification NO

Basic model: 2.5 GBq (67.5 mCi)

BSA model: (BSA[m²] – 0.2) + TI[%]/100 = 1.85 GBq (50.1 mCi)

Liver Dose [Gy] = A [GBq] x (1-LS) x 49.7 [Gy-kg/GBq] / M_{liver} [kg]
= 44.7 Gy (< 80 Gy)

Lung Dose [Gy] = A [GBq] x LS x 49.7 [Gy-kg/GBq] / M_{lung} [kg]
= 6.8 Gy (<25 Gy)

Patient imaging on day of ^{90}Y-Therapy

- Interventional Radiologist in Angiography suite
  - verify catheter placement, assess flow
  - deliver ^{90}Y-microspheres
- NM Planar & SPECT ^{90}Y-bremsstrahlung imaging
  - 79keV/26% window, MELP collimation, 128x128 matrix, 4.8 mm² pixels, 128 views/360°, 28 s/view, non-circular step-shoot
  - Assess delivery and distribution of ^{90}Y-microspheres
- Follow-up evaluations at 2-3 months – CT or MRI



Pre and Post ^{90}Y-microsphere therapy

PRIOR	THERAPY	POST

CT 3-June-2008



Y-90 SPECT/CT
2-July-2008



CT 5-Sept-2008



Tc-99m MAA SPECT/CT
24-June-2008



Tc-99m MAA SPECT/CT
2-Sept-2008

SPECT Concordance: ^{99m}Tc-MAA & ^{90}Y

Tc-99m MAA SPECT/CT 24-June-2008

Y-90 SPECT/CT 2-July-2008

Fused SPECT: Tc-99m MAA and Y-90



SAM Question 1

The physical properties of Yttrium-90 that makes it well suited for internal radionuclide therapy are that ^{90}Y is a pure β^- emitter with a max. energy of 2.28 MeV corresponding to a:

23% A. maximum tissue penetration depth of ~0.1 mm

25% B. maximum tissue penetration depth of ~1 mm

28% C. maximum tissue penetration depth of ~10 mm

25% D. maximum tissue penetration depth of ~100 mm

SAM Question 1: Answer

- The physical properties of Yttrium-90 that makes it well suited for internal radionuclide therapy are that ^{90}Y is a pure β^- emitter with a maximum energy of 2.28 MeV corresponding to a:
  A. maximum tissue penetration depth of ~0.1 mm
  B. maximum tissue penetration depth of ~1 mm
  C. maximum tissue penetration depth of ~10 mm
  D. maximum tissue penetration depth of ~100 mm

- *Reference: Sarfaraz M, Kennedy AS, Lodge MA, Li XA, Wu X, Yu CX, "Radiation absorbed dose distribution in a patient treated with yttrium-90 microspheres for hepatocellular carcinoma," Medical Physics 31(9):2449-53, 2004*

SAM Question 2

The most common route of ^{90}Y-microsphere administration for liver–directed therapy is:

24% A. Peri-tumoral injection
25% B. Implantation of 90Y-brachytherapy seeds
25% C. Systematic administration via intravenous injection
26% D. Trans-hepatic arterial administration via catheter

SAM Question 2: Answer

- The most common route of ^{90}Y-microsphere administration for liver–directed therapy is:
  A. Peri-tumoral injection
  B. Implantation of 90Y-brachytherapy seeds
  C. Systematic administration via intravenous injection
  D. Trans-hepatic arterial administration via catheter
- *Reference: Murthy R, Nunez R, Szklaruk J, et al., "Yttrium-90 microsphere therapy for hepatic malignancy: devices, indications, technical considerations, and potential complications," Radiographics 25(Supplement 1):S41-55, 2005*

SAM Question 3

The lung shunt fraction (LSF) based on ^{99m}Tc-MAA Planar images, used to estimate lung absorbed doses from ^{90}Y-microsphere therapy, is calculated as:

23% A. $\text{Lung Shunt Fraction}(\%) = \frac{\text{Lung Counts}}{\text{Liver Counts}} \times 100$

26% B. $\text{Lung Shunt Fraction}(\%) = \frac{\text{Liver Counts}}{\text{Lung Counts}} \times 100$

27% C. $\text{Lung Shunt Fraction}(\%) = \frac{\text{Lung Counts}}{\text{Lung Counts} + \text{Liver Counts}} \times 100$

25% D. $\text{Lung Shunt Fraction}(\%) = \frac{\text{Lung Counts} + \text{Liver Counts}}{\text{Lung Counts}} \times 100$

SAM Question 3: Answer

- The lung shunt fraction (LSF) based on ^{99m}Tc-MAA Planar images, used to estimate lung absorbed doses from ^{90}Y-microsphere therapy, is calculated as:

A. $$\text{Lung Shunt Fraction (\%)} = \frac{\text{Lung Counts}}{\text{Liver Counts}} \times 100$$

B. $$\text{Lung Shunt Fraction (\%)} = \frac{\text{Liver Counts}}{\text{Lung Counts}} \times 100$$

C. $$\text{Lung Shunt Fraction (\%)} = \frac{\text{Lung Counts}}{\text{Lung Counts} + \text{Liver Counts}} \times 100$$

D. $$\text{Lung Shunt Fraction (\%)} = \frac{\text{Lung Counts} + \text{Liver Counts}}{\text{Lung Counts}} \times 100$$

- *Reference: Gulec S, Mesoloras G, Stabin M, "Dosimetric techniques in 90Y-microsphere therapy of liver cancer: The MIRD equations for dose calculations," J Nuclear Medicine 47:1209–11, 2006*

SAM Question 4

The typical range of planned absorbed doses to target liver tissue in ^{90}Y-microsphere internal radionuclide therapies is around:

25% A. 40 – 60 cGy
24% B. 80 – 120 cGy
27% C. 40 – 60 Gy
25% D. 80 – 120 Gy

SAM Question 4: Answer

- The typical range of planned absorbed doses to target liver tissue in ^{90}Y-microsphere internal radionuclide therapies is around:
  - A. 40 – 60 cGy
  - B. 80 – 120 cGy
  - C. 40 – 60 Gy
  - D. 80 – 120 Gy
- *Reference: Salem R, Thurston KG, "Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies—Part 1: Technical and methodologic considerations," J Vasc Interv Radiology 17:1251–1278, 2006*

Limitations of Planning Dosimetry

- Not intended to calculate dose to individual tumors
- Uses conservative assumptions to ensure safety
- Assumes uniform uptake of microspheres in tumor and normal liver compartments



- Three-compartment model: lung, liver, and tumor
  - Accounts for differential uptake of microspheres in liver versus tumor
  - All tumors, independent of their sizes or locations, grouped into the tumor compartment with a single uptake value

(Ho et al., EJNM 23, 947-52, 1996)

Three-compartment Partition model

- Additional information needed (Ho et al., EJNM 23, 947-52, 1996)
  - Tumor burden (M_{tumor}) and Tumor uptake ratio (R)
- Estimation of fractional Tumor Involvement (TI)
  - $M_{total} = M_{liver} + M_{tumor}$
  - $M_{tumor} = TI \times M_{total}$ and $M_{liver} = (1-TI) \times M_{total}$
- Estimation of Tumor Uptake Ratio (R)

$$R = \frac{\text{Tumor MAA uptake [counts/pixel]}}{\text{Liver MAA uptake [counts/pixel]}}$$

- A_{liver} [mCi] = A [mCi] x (1-LS) x M_{liver} / (M_{liver} + R x M_{tumor})
- A_{tumor} [mCi] = A [mCi] x (1-LS) x R x M_{tumor} / (M_{liver} + R x M_{tumor})
- $Dose_{organ}$ [Gy] = A_{organ} [GBq] x 49.7 [Gy-kg/GBq] / M_{organ} [kg]

Example Calculation: Dose

- LS = 7.35%
- Total Activity = 222 mCi
- Total liver = 2.76 kg
- TI = 45%
- T/N: R = 632.9/32.8 = 19.3
- Normal Liver
  - Mass = 1.52 kg
  - Activity = 12.3 mCi
  - Dose = 14.7 Gy
- Tumor
  - Mass = 1.24 kg
  - Activity = 193.4 mCi
  - Dose = 284.5 Gy



- Prior estimate of liver dose = 137 Gy with T/N=1

Three Compartment Model Dose Estimates



(MacLellan & Kappadath, SNM 2012)

- 3CM doses are relatively insensitive to tumor uptake threshold levels
- 3CM yielded higher doses to tumor and lower doses to normal liver compared to BSA for both ^{99m}Tc-MAA and ^{90}Y-bremssthralung SPECT/CT
- Differences in calculated dose between the 3CM and BSA models are larger for the ^{99m}Tc-MAA scans than with the ^{90}Y scans

Three Compartment Model Dose Estimates



(MacLellan & Kappadath, SNM 2012)

- Significant correlation ($p<0.001$ @75% isocount threshold) was observed between the ^{90}Y and ^{99m}Tc-MAA tumor dose estimates but not for normal liver dose estimates
- The ^{90}Y images yielded lower estimates for tumor doses (72% on average at 75% threshold) and higher normal liver doses (150% on average at 75% threshold)

^{90}Y-PET/CT Images

- ^{90}Y also emits β^+ at low yields (31.9 ±0.5 ppm) via internal pair-production of 0^+–0^+ transition of ^{90}Zr

(Greenberg & Deutsch 1956, Selwyn et al, 2007)



(Kappadath & Mawlawi, SNM 2011)



(Gates et al., JNM 52, 2011)

Assay of ^{90}Y Activity

- Dose calibration setting determined on-site with calibrated ^{90}Y activity

Dose Calibrator S/N	Calibration Number
15722	47 x 10
15724	47 x 10
15725	47 x 10
15728	47 x 10
15729	47 x 10
151034	45 x 10
510034	46 x 10

- SIR-Spheres
  - Activity delivered as 81 mCi microspheres in water, 5 ml total volume
  - Draw microspheres solution by volume to desired activity

D. Divide activity by the number of ml in vial to calculate mCi per ml

Original activity in vial = 80 mCi ÷ 5 ml = 16 mCi/ml Concentration

2. Calculate volume required for the prescribed dose:

(Divide the prescribed dose by the mCi per ml calculated above)

Prescribed dose 48 mCi ÷ 16 mCi/ml Concentration = 3 ml required

4. Measure residual to estimate activity drawn:

Residual activity = 34 mCi

Original 80 mCi – Residual 34 mCi in dose vial = 46 mCi in syringe

Assay of ^{90}Y Activity

- TheraSphere
  - Modification of the delivered activity is not allowed
  - Ordered activity would account for day/time of therapy

Target Volume (cc):	929.0		**Target Liver Mass (kg):**	0.957
Desired Dose (Gy):	120			
Time Zone Variance (h):	1	Variance from Eastern Standard Time (EST)		
Lung Shunt Fraction (% LSF):	5.59%	Imported automatically from Lung Shunt Calculation worksheet		
Anticipated Residual Waste (%):	2.00%	Optional estimated value		
Previous Dose to the Lungs (Gy):	0.0			
Required Activity at Administration (GBq):	2.48	This value is corrected for LSF and Residual Waste if values are entered above		

Activity Size Selected (GBq):	7
Date & Time for Administration:	Thursday

Dose Delivered (Gy) for: 5 GBq Activity

Time	Sunday	Monday	Tuesday	Wednesday	Thursday	Friday
8:00 AM	Calibration Day @ 12:00 EST	193	149	115	88	68
12:00 PM		184	142	110	85	65
4:00 PM		177	136	105	81	63
8:00 PM		169	131	101	78	60

Dose Delivered (Gy) for: 7 GBq Activity

Time	Sunday	Monday	Tuesday	Wednesday	Thursday	Friday
8:00 AM	Calibration Day @ 12:00 EST	270	208	160	124	96
12:00 PM		258	199	154	119	91
4:00 PM		247	191	147	114	88
8:00 PM		237	183	141	109	84

Dose Delivered (Gy) for: 10 GBq Activity

Time	Sunday	Monday	Tuesday	Wednesday	Thursday	Friday
8:00 AM	Calibration Day @ 12:00 EST	385	297	229	177	136
12:00 PM		369	285	220	169	131
4:00 PM		353	273	210	162	125
8:00 PM		338	261	201	155	120

Calculation of Administered Activity

- Percentage of activity delivered to the patient can be based on ion-chamber exposure rate measurements
  - Before administration: dose-vial in acrylic shield
  - After administration: the 2L Nalgene jar with beta shield containing waste and residual activity



- The percentage of activity delivered to the patient

$$\text{Activity Delivered}[\%] = 100 \times \left(1 - \frac{\text{Waste measurement after therapy}}{\text{Dose vial measurement before therapy}}\right)$$

- Activity delivered to patient

$$\text{Activity Delivered}[\text{mCi}] = \text{Dose Vial Activity}[\text{mCi}] \times \text{Activity Delivered}[\%] / 100$$

^{90}Y-microsphere Therapy Preparation

© TheraSphere

Radiation Safety

- Transport
  - Acrylic shield will stop all beta emission and keep exposure rate low
  - <2 mR/hr at 1 m for up to 300 mCi of activity in acrylic shield
- During administration
  - Highest potential for exposure is to administering staff in IR suite when spheres are located in catheter between v-vial and the patient
  - Stand behind shield and maintain distance
- Survey personnel leaving the room with GM survey meter
- Store radioactive material until the container surface radioactivity cannot be distinguished from background
- Long-lived contaminants ^{91}Y and ^{88}Y may be present with reactor production of ^{90}Y
  - Long-lived radioactive by-products may not be a problem using carrier free ^{90}Y from a ^{90}Sr generator

Some Challenges for ^{90}Y-Therapy

- ROIs on 2D Planar images introduce uncertainties
  - Estimate lung shunt fraction and lung dose
  - Split dose calculation – lobar separation of liver not visualized
- MAA is a sub-optimal surrogate for microspheres
  - Biologic degradation time 1–3 hours → free 99mTc-pertechnatate
  - Free 99mTc biodistribution differs from MAA; thyroid & stomach uptakes free 99mTc ← introduce error in LSF
  - Non-spherical shape; Size range 10-to-100 µm
- Additional objective measures of response
  - Tumor volume reduction is the mainstay (Gray et al, Aus & NZ J Surgery 62, 1992; Van Hazel et al, J Sur Onc 88, 2004; Lau et al, IJROBP 40, 1998; Sangro et al, IJROBP 66, 2006)
  - Metabolic response: observed in higher proportion than an CT-based anatomical response for mCRC ($p<0.0002$) (Wong et al, EJNMMI 29, 2002)
  - Functional response: >50% change in TLG at 6 weeks for mCRC lesions with tumor doses >46 Gy (Flamen et al, PMB 53, 2008)

Summary

- ^{90}Y-microsphere therapy is a promising and an increasingly popular treatment option for palliative care of patients with metastatic liver disease and unresectable HCC
- Decreased tumor volumes and increased time to tumor progression have been reported
- New objective measures of response are under investigation
- Improved imaging and dosimetry are beginning to yield more accurate dose estimates